Compare Aurora Cannabis Inc (ACB) vs Procter & Gamble Co (PG) Price & Performance

Aurora Cannabis (ACB) trades at $2.99, up 0.34% with a bullish technical signal despite mixed earnings. The company achieved record annual medical cannabis revenue growth of 18% YoY to $288.6 million in FY2026, but faces margin pressure from Canadian reimbursement changes. Recent Q1 2027 earnings beat expectations with $0.04 EPS versus -$0.13 estimate, though revenue declined to $67.6 million. The stock shows strong institutional support with shareholder approval of board measures and EU-GMP certification for international expansion.

ACB presents a high-risk opportunity with significant volatility. While international medical cannabis growth and operational improvements provide upside potential, persistent net losses, negative ROE/ROA, and Canadian market challenges create substantial headwinds. Analyst consensus remains cautious with only 21% buy ratings, reflecting concerns about profitability timeline and competitive pressures in the evolving cannabis sector.

Procter & Gamble (PG) trades at $145.21, down 0.38% on the day, with a bearish technical signal from moving averages. The company maintains strong fundamentals with consistent earnings beats, including Q2 2026 EPS of $1.43 beating expectations of $1.41. Revenue reached $84.28 billion in 2025 with net income of $15.97 billion, supported by a robust 18.44% net margin and 30.13% ROE. Recent developments include a new WNBA partnership and a $1.09 dividend declaration for August 2026 payment.

PG offers stable dividend income with 69 consecutive years of increases, but faces premium valuation concerns at 22.12 P/E ratio. Analyst consensus targets $161.20 with 53% buy ratings, suggesting 11% upside potential. Key risks include soft demand outlook and elevated valuation multiples compared to peers. The stock presents a defensive investment opportunity amid market volatility, though near-term growth appears modest.